Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.67 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.61 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.59 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.59 |
| ▸ | F2 | P00734 | 4/20 | 0.58 |
| ▸ | TFPI | P10646 | 3/20 | 0.58 |
| ▸ | APLNR | P35414 | 1/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | NPY4R | P50391 | 1/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855908 | 0.91 | MC4R (0.68) | MC4RC5AR1NMUR2NMUR1CXCR4 | |
| SCHEMBL30432142 | 0.90 | MC4R (0.73) | MC4RC5AR1NMUR2NMUR1CXCR4 | |
| SCHEMBL30176412 | 0.89 | MC4R (0.63) | MC4RNMUR2NMUR1CXCR4F2 | |
| SCHEMBL30723556 | 0.88 | F2 (0.58) | MC4RF2APLNR | |
| SCHEMBL30432686 | 0.88 | C5AR1 (0.66) | MC4RC5AR1TFPIAPLNRNPY1R | |
| SCHEMBL29638066 | 0.88 | MC4R (0.61) | MC4RC5AR1NMUR2NMUR1F2 | |
| SCHEMBL30495631 | 0.88 | F2 (0.66) | MC4RNMUR2NMUR1CXCR4F2 | |
| SCHEMBL29638059 | 0.88 | MC4R (0.61) | MC4RC5AR1NMUR2NMUR1F2 | |
| SCHEMBL29695502 | 0.88 | APLNR (0.64) | MC4RC5AR1NMUR2NMUR1F2 | |
| SCHEMBL29593115 | 0.87 | C5AR1 (0.69) | MC4RC5AR1F2TFPINPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268999-A1 | Treatment and Prophylaxis of Amyloidosis | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268999-A1 | Treatment and Prophylaxis of Amyloidosis | TTR, APP, MME | MC4R 4368/4885C5AR1 2765/4885NMUR2 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.